



RECEIVED

NOV 29 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900
(Case No. 00,422)

PATENT

In re: Application of: Yan

Serial No.: 09/619,198

Filed: July 19, 2000

For: VGF Polypeptides and Methods
of Treating VGF-Related Disorders

Before the Examiner: F. Hamud

Group Art Unit: 1647

Commissioner for Patents
Washington, D.C. 20231


Sir/Madam:

TRANSMITTAL LETTER

1. We are transmitting herewith the attached papers for the above-identified application:
Response to Restriction Requirement, Petition for Extension of Time, and postcard.
2. A check in the amount of \$110.00 for an extension of time is attached.
3. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner for Patents, Box Provisional Patent Application, Washington D.C. 20231, on November 6, 2001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Dated: November 6, 2001

By: 
Donald Zuhn, Ph.D.
Reg. No. 48,710



RECEIVED

NOV 29 2001

#3
nb
12/03/01

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 00,422)

PATENT

In re Application of: Yan)

Serial No.: 09/619,198)

Before the Examiner: F. Hamud

Filed: July 19, 2000)

Group Art Unit: 1647

For: VGF Polypeptides and Methods)
of Treating VGF-Related Disorders)

Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

RESPONSE TO RESTRICTION REQUIREMENT
MAILED SEPTEMBER 29, 2001

Responsive to the Restriction Requirement, mailed September 27, 2001, Applicants elect to prosecute claims 1-4, 5(a), and 6-13, designated as Group I by the Examiner, and the polypeptide of SEQ ID NO: 7, with traverse. According to the terms of the Restriction Requirement, the claims of Group I are directed towards an isolated polypeptide, an isolated polypeptide with at least one conservative amino acid substitution, a fusion protein, a composition comprising said polypeptide and a pharmaceutically acceptable carrier, and said polypeptide which is covalently modified with a water-soluble polymer. The basis for Applicants' traversal of the requirement is as follows.

Applicants respectfully submit that there will be no undue hardship on the Office in performing a search with respect to the polypeptides of Groups I, IV, and V, since the polypeptides of the Groups IV and V constitute fragments of the polypeptides of Group I. Furthermore, since the polypeptides of SEQ ID NOs: 1-10 are not entirely unrelated sequences – in that each polypeptide is a fragment of a single full-length polypeptide, VGF polypeptide (Appendix A) – Applicants contend that there would be no undue hardship on the office in performing a search with respect to the polypeptides of SEQ ID NOs: 1-10.


Applicants enclose a petition for a one-month extension of time. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.


If Examiner Hamud believes it to be helpful, the Examiner is invited to contact the undersigned representative by telephone at (312) 913-0001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Dated: November 6, 2001

By:


Donald Zuhn, Ph.D.
Reg. No. 48,710



RECEIVED

NOV 2 9 2001

TECH CENTER 1600/2900

Appendix A

	10	20	30	40	50	60
human VGF	MKALRLSASA	LFCLLLINGL	GAAPPGRPEA	QPPPLSSEHK	EPVAGDAVPG	PKDGSAPFVR
	70	80	90	100	110	120
human VGF	GARNSEPQDE	GELFQGVDP	ALAAVLLQAL	DRPASPPAPS	GSQQGPPEEA	AEALLTETVR
	130	140	150	160	170	180
human VGF	SQTHSLPAAG	EPEPAAPPRP	QTPENGPEAS	DPSEEELEALA	SLLQELRDFS	PSSAKRQOET
	190	200	210	220	230	240
human VGF	AAAETETRTH	TLTRVNLESP	GPERVWRASW	GEFQARVPER	APLPPPAPSQ	FQARMPDSGP
	250	260	270	280	290	300
human VGF	LPETHKFGEG	VSSPKTHLGE	ALAPLSKAYQ	GVAAPFPKAR	RAESALLGGS	EAGERLLQOQ
6. VGF-2						
[80]					10	
					LGGS	EAGERLLQOQ>
human VGF					LGGS	EAGERLLQOQ
	310	320	330	340	350	360
human VGF	LAQVEAGRRO	AEATRQAAAQ	EERLADLASD	LLLQYLLQGG	ARQRLGGRG	LQEAAEERES
2. VGF-5		10	20	30	40	50
[198]	Q	AEATRQAAAQ	EERLADLASD	LLLQYLLQGG	ARQRdLGGRG	LQEtqqEREN>
human VGF	Q	AEATRQAAAQ	EERLADLASD	LLLQYLLQGG	ARQRLGGRG	LQEAAEERES
6. VGF-2	0					
[80]	LAQVEA>					
human VGF	LAQVEA					
	370	380	390	400	410	420
human VGF	AREEEAEQE	RRGGEERVGE	EDEEAAEAAE	AEADEAERAR	QNALLFAEEE	DGEAGAEDKR
2. VGF-5						
[198]	eR-EEAEQE>					
human VGF	AREEEAEQE					
4. VGF-6		10	20	30	40	
[156]	gGGEdeVGE	EDEEAA-eAE	AEAEeAERAR	QNALLFAEEE	DGEAGAE>	
human VGF	RGGEERVGE	EDEEAAEAAE	AEADEAERAR	QNALLFAEEE	DGEAGAE	

[illegible]